Search

Your search keyword '"Tuphan Kanti Dolai"' showing total 90 results

Search Constraints

Start Over You searched for: Author "Tuphan Kanti Dolai" Remove constraint Author: "Tuphan Kanti Dolai" Topic medicine Remove constraint Topic: medicine
90 results on '"Tuphan Kanti Dolai"'

Search Results

1. Geo-environmental factors and the effectiveness of mulberry leaf extract in managing malaria

2. Study of epidemiological behaviour of malaria and its control in the Purulia district of West Bengal, India (2016–2020)

3. Does Thyroid dysfunction correlates with iron overload in Eβ thalassemia patients? A study from a tertiary care thalassemia center in India

4. Study of arsenic exposure in oral/oropharyngeal carcinoma in West Bengal

5. Vaccination for the novel coronavirus disease in hematological disorders

6. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children

7. Profile of patients with Myelodysplastic syndrome: A report from a tertiary care teaching hospital from Eastern India

8. Myeloid sarcoma: experience from a hematology care centre of Eastern India

9. Challenges in Care of Children with Acute Leukemia in a Government Hospital in India: A Retrospective Analysis

10. A Pilot Study on Probing of Imatinib Induced Platelet Dysfunction in Patients with Chronic Myeloid Leukemia-Chronic Phase and Absence of Associated Bleeding Manifestation: Trying to Solve an Enigma

11. Bone infarct (osteonecrosis) as late side effect of steroid in acute lymphoblastic leukemia survivor

12. Is Low Dose a New Dose to Initiate Hemophilia A Prophylaxis? – A Systematic Study in Eastern India

13. Changes in Different Cytokines (IL-2, TNF-α, and IFN-γ) Profile in Acquired Aplastic Anemia Patients: A Study From Eastern India

14. Inherited and acquired thrombophilia as a modifier of clinical course of chronic immune thrombocytopenia

15. Revisiting fetal hemoglobin inducers in beta-hemoglobinopathies: a review of natural products, conventional and combinatorial therapies

16. Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

17. Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

18. Response to Immunosuppressive Therapy in Acquired Aplastic Anaemia: Experience of a Tertiary Care Centre from Eastern India

20. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

21. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies

22. Indian Society of Hematology and Blood Transfusion (ISHBT) Consensus Document on Hematological Practice During COVID-19 Pandemic

23. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

24. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

25. Implications of Population Screening for Thalassemias and Hemoglobinopathies in Rural Areas of West Bengal, India: Report of a 10-Year Study of 287,258 Cases

26. Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India

27. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

28. Azacitidine Causing Generalised Skin Rash: A Rare Side Effect

29. Efficacy of Dichlorophenolindophenol (DCIP) as Screening Test for Hb E: Revisited

30. Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

31. Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

32. Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

33. Pattern of Sickle Cell Disorders: A Study from a Tertiary Care Center in Eastern Part of India

34. Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

35. Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study

36. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India

37. Predictors for Transfusion Requirement in Haemoglobin E-β Thalassemia

38. Author response for 'Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: an international multicenter randomized trial'

39. MicroRNA expression patterns in HbE/β-thalassemia patients: The passwords to unlock fetal hemoglobin expression in β-hemoglobinopathies

40. The prevalence of anemia among the tribal children from the western districts of West Bengal, India

41. Outcome of Cyclosporine Monotherapy in Patients of Aplastic Anemia: Experience of a Tertiary Care Hospital in Eastern India

42. Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome and a brief review

43. Primary bone lymphoma with multifocal osteolytic lesions: a rare case report with review of literature

44. Hemarthrosis in hemoglobin E beta thalassemia: a rare clinical scenario

45. An account of congenital rare bleeding disorders: a systematic study from a tertiary care centre in Eastern India

46. Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study

47. OUTBREAK OF BURKHOLDERIA CEPACIA INFECTION: A SYSTEMATIC STUDY IN A HEMATOLOGY-ONCOLOGY UNIT OF A TERTIARY CARE HOSPITAL FROM EASTERN INDIA

48. Comparative study of bone marrow and blood plasma levels of IL-2 in aplastic anaemia and their relationship with disease severity

49. Incidence of Fanconi anaemia in phenotypically normal aplastic anaemia patients in West Bengal

50. Correspondence

Catalog

Books, media, physical & digital resources